Daniel A. Kuppers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel A. Kuppers has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Adrian R. Black
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA
1 shared publication- Alexander Yu
Department of Surgery, Division of Urology, University of Texas Medical Branch, Galveston, TX
1 shared publication - Alexandra Corella
UCSF, San Francisco, CA
1 shared publication - Arja Kaipainen
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
1 shared publication - Betty Sue Pace
Augusta University, Augusta, Georgia, United States
1 shared publication - Elahe A. Mostaghel
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
1 shared publication
Latest Publications
- 10 July 2026
- Published by SAGE Publications in Tissue Engineering Part C: Methods
- Vol. 32 (7) , 267-276
Applications of the Human Bone Marrow Organoid System to Study Hematopoiesis and Anemia Stress
Hematopoietic stem and progenitor cells (HSPCs) are precisely organized within specialized bone marrow niches containing hematopoietic and nonhematopoietic cell types. Physiologically accurate human models of this niche environment that include functional HSPCs have been lacking until recently. Using induced pluripotent stem cells (iPSCs) grown in mixed-matrix hydrogels, vascularized three-dimensional human bone marrow organoids (hBMOs) can now be generated that contain mesenchymal, endothelial, and hematopoietic cells, all vital components of the bone marrow niche. While hBMOs have been shown to support engraftment of normal and malignant cells, there are numerous opportunities to use hBMOs for developing a wider experimental toolkit to test gene functions and stress responses. Here, we establish two new applications for the hBMO platform. First, we demonstrate successful engraftment of gene-edited CD34 + cells from healthy donors, enabling direct investigation of gene-specific effects on human hematopoiesis in a defined microenvironment. Gene-edited engrafted HSPCs are maintained in hBMOs for 7 days and undergo multilineage differentiation. Second, we adapted a method to induce stress erythropoiesis—a response to acute anemia in mice and humans—in hBMOs, resulting in robust expansion of immunophenotypically defined hematopoietic progenitors and erythroid populations. These two advances expand the laboratory uses for hBMOs and establish this system as a versatile platform for studying human hematopoiesis and erythropoiesis, stress responses, and gene functions within a physiologically relevant bone marrow microenvironment.
- 10 July 2026
- Published by SAGE Publications in Tissue Engineering Part C: Methods
- Vol. 32 (7) , 267-276
Applications of the Human Bone Marrow Organoid System to Study Hematopoiesis and Anemia Stress
Hematopoietic stem and progenitor cells (HSPCs) are precisely organized within specialized bone marrow niches containing hematopoietic and nonhematopoietic cell types. Physiologically accurate human models of this niche environment that include functional HSPCs have been lacking until recently. Using induced pluripotent stem cells (iPSCs) grown in mixed-matrix hydrogels, vascularized three-dimensional human bone marrow organoids (hBMOs) can now be generated that contain mesenchymal, endothelial, and hematopoietic cells, all vital components of the bone marrow niche. While hBMOs have been shown to support engraftment of normal and malignant cells, there are numerous opportunities to use hBMOs for developing a wider experimental toolkit to test gene functions and stress responses. Here, we establish two new applications for the hBMO platform. First, we demonstrate successful engraftment of gene-edited CD34 + cells from healthy donors, enabling direct investigation of gene-specific effects on human hematopoiesis in a defined microenvironment. Gene-edited engrafted HSPCs are maintained in hBMOs for 7 days and undergo multilineage differentiation. Second, we adapted a method to induce stress erythropoiesis—a response to acute anemia in mice and humans—in hBMOs, resulting in robust expansion of immunophenotypically defined hematopoietic progenitors and erythroid populations. These two advances expand the laboratory uses for hBMOs and establish this system as a versatile platform for studying human hematopoiesis and erythropoiesis, stress responses, and gene functions within a physiologically relevant bone marrow microenvironment.
- Open Access
- 8 January 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (2)
An intergenic silencer region regulates HBG expression
- 8 January 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (2)
Open AccessAn intergenic silencer region regulates HBG expression
- Open Access
- 23 May 2023
- Published by Springer Nature
CD34+ Cell RNP Nucleofection v2
Human CD34+ hematopoietic stem and progenitor cells (HSPCs) are a standard source of cells for clinical HSC transplantations as well as experimental xenotransplantation to generate “humanized mice”. To further extend the range of applications of these humanized mice, we developed a protocol to efficiently edit the genomes of human CD34+ HSPCs before transplantation. In the past, manipulating HSPCs has been complicated by the fact that they are inherently difficult to transduce with lentivectors, and rapidly lose their stemness and engraftment potential during in vitro culture. However, with optimized nucleofection of sgRNA:Cas9 ribonucleoprotein complexes, we are now able to edit a candidate gene in CD34+ HSPCs with almost 100% efficiency, and still be able to generate a humanized mouse with high engraftment and multilineage differentiation.
- 23 May 2023
- Published by Springer Nature
Open AccessCD34+ Cell RNP Nucleofection v2
Human CD34+ hematopoietic stem and progenitor cells (HSPCs) are a standard source of cells for clinical HSC transplantations as well as experimental xenotransplantation to generate “humanized mice”. To further extend the range of applications of these humanized mice, we developed a protocol to efficiently edit the genomes of human CD34+ HSPCs before transplantation. In the past, manipulating HSPCs has been complicated by the fact that they are inherently difficult to transduce with lentivectors, and rapidly lose their stemness and engraftment potential during in vitro culture. However, with optimized nucleofection of sgRNA:Cas9 ribonucleoprotein complexes, we are now able to edit a candidate gene in CD34+ HSPCs with almost 100% efficiency, and still be able to generate a humanized mouse with high engraftment and multilineage differentiation.
- 3 October 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (19)
Molecular determinants of response to high-dose androgen therapy in prostate cancer
Clinical trials of high-dose androgen (HDA) therapy for prostate cancer (PC) have shown promising efficacy but are limited by lack of criteria to identify likely responders. To elucidate factors that govern the growth-repressive effects of HDAs, we applied an unbiased integrative approach using genetic screens and transcriptional profiling of PC cells with or without demonstrated phenotypic sensitivity to androgen-mediated growth repression. Through this comprehensive analysis, we identified genetic events and related signaling networks that determine the response to both HDA and androgen withdrawal. We applied these findings to develop a gene signature that may serve as an early indicator of treatment response and identify men with tumors that are amenable to HDA therapy.
- 3 October 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (19)
Molecular determinants of response to high-dose androgen therapy in prostate cancer
Clinical trials of high-dose androgen (HDA) therapy for prostate cancer (PC) have shown promising efficacy but are limited by lack of criteria to identify likely responders. To elucidate factors that govern the growth-repressive effects of HDAs, we applied an unbiased integrative approach using genetic screens and transcriptional profiling of PC cells with or without demonstrated phenotypic sensitivity to androgen-mediated growth repression. Through this comprehensive analysis, we identified genetic events and related signaling networks that determine the response to both HDA and androgen withdrawal. We applied these findings to develop a gene signature that may serve as an early indicator of treatment response and identify men with tumors that are amenable to HDA therapy.